Shots:

• The termination is based on results from P-IIb study- assessing Novexatin vs PBO- which was unable to meet a main goal of study under FDA guidelines with no superiority over PBO
• In 2013- Taro entered into license and co-development agreement with NovaBiotics for its novel antifungal peptide Novexatin
• Novexatin is a fast-acting topical drug candidate currently evaluated in P-IIb study for the treatment of fungal nail infections (onychomycosis)

Ref: Taro Pharmaceuticals  | Image: Taro